» Articles » PMID: 24378538

CCR7 Provides Localized Access to IL-2 and Defines Homeostatically Distinct Regulatory T Cell Subsets

Overview
Journal J Exp Med
Date 2014 Jan 1
PMID 24378538
Citations 229
Authors
Affiliations
Soon will be listed here.
Abstract

Immune tolerance and activation depend on precise control over the number and function of immunosuppressive Foxp3(+) regulatory T (T reg) cells, and the importance of IL-2 in maintaining tolerance and preventing autoimmunity is clear. However, the homeostatic requirement for IL-2 among specific populations of peripheral T reg cells remains poorly understood. We show that IL-2 selectively maintains a population of quiescent CD44(lo)CD62L(hi) T reg cells that gain access to paracrine IL-2 produced in the T cell zones of secondary lymphoid tissues due to their expression of the chemokine receptor CCR7. In contrast, CD44(hi)CD62L(lo)CCR7(lo) T reg cells that populate nonlymphoid tissues do not access IL-2-prevalent regions in vivo and are insensitive to IL-2 blockade; instead, their maintenance depends on continued signaling through the co-stimulatory receptor ICOS (inducible co-stimulator). Thus, we define a fundamental homeostatic subdivision in T reg cell populations based on their localization and provide an integrated framework for understanding how T reg cell abundance and function are controlled by unique signals in different tissue environments.

Citing Articles

Type 2 conventional dendritic cell functional heterogeneity: ontogenically committed or environmentally plastic?.

Leon B Trends Immunol. 2025; 46(2):104-120.

PMID: 39843310 PMC: 11835539. DOI: 10.1016/j.it.2024.12.005.


Interleukin-2 receptor signaling acts as a checkpoint that influences the distribution of regulatory T cell subsets.

Shouse A, Villarino A, Malek T iScience. 2025; 27(12):111248.

PMID: 39759017 PMC: 11700635. DOI: 10.1016/j.isci.2024.111248.


An IL-2 mutein increases regulatory T cell suppression of dendritic cells via IL-10 and CTLA-4 to promote T cell anergy.

Jamison B, Lawrance M, Wang C, DeBerg H, Ziegler L, Sansom D Cell Rep. 2024; 43(11):114938.

PMID: 39488830 PMC: 11602548. DOI: 10.1016/j.celrep.2024.114938.


Treg Cell Therapeutic Strategies for Breast Cancer: Holistic to Local Aspects.

Zhang H, Felthaus O, Eigenberger A, Klein S, Prantl L Cells. 2024; 13(18.

PMID: 39329710 PMC: 11429654. DOI: 10.3390/cells13181526.


Dynamic chromatin architecture identifies new autoimmune-associated enhancers for and novel genes regulating CD4+ T cell activation.

Pahl M, Sharma P, Thomas R, Thompson Z, Mount Z, Pippin J Elife. 2024; 13.

PMID: 39302339 PMC: 11418197. DOI: 10.7554/eLife.96852.


References
1.
Dong C, Nurieva R . Regulation of immune and autoimmune responses by ICOS. J Autoimmun. 2003; 21(3):255-60. DOI: 10.1016/s0896-8411(03)00119-7. View

2.
Cheng G, Yu A, Dee M, Malek T . IL-2R signaling is essential for functional maturation of regulatory T cells during thymic development. J Immunol. 2013; 190(4):1567-75. PMC: 3563871. DOI: 10.4049/jimmunol.1201218. View

3.
Hall A, Beiting D, Tato C, John B, Oldenhove G, Gonzalez Lombana C . The cytokines interleukin 27 and interferon-γ promote distinct Treg cell populations required to limit infection-induced pathology. Immunity. 2012; 37(3):511-23. PMC: 3477519. DOI: 10.1016/j.immuni.2012.06.014. View

4.
Vignali D, Collison L, Workman C . How regulatory T cells work. Nat Rev Immunol. 2008; 8(7):523-32. PMC: 2665249. DOI: 10.1038/nri2343. View

5.
Pierson W, Cauwe B, Policheni A, Schlenner S, Franckaert D, Berges J . Antiapoptotic Mcl-1 is critical for the survival and niche-filling capacity of Foxp3⁺ regulatory T cells. Nat Immunol. 2013; 14(9):959-65. PMC: 4128388. DOI: 10.1038/ni.2649. View